The Drug Enforcement Agency refused to relax restrictions on cannabis last week, meaning marijuana will remain Schedule 1 — the strictest category of the Controlled Substances Act, designated for dangerous and addictive drugs with no medical value — in spite of growing evidence that marijuana is relatively safe and medically useful.
The DEA is claiming marijuana lacks medical value. If that’s true, why did the U.S. government file a patent for cannabis — stating that the plant has multiple therapeutic benefits — way back in 1999?
BYPASS THE CENSORS
Sign up to get unfiltered news delivered straight to your inbox.
That’s what some medical marijuana advocates are asking after the DEA declined to loosen federal restrictions on cannabis last week.
To highlight the contradiction, they’re sharing photos of their hands featuring the patent number: 6,630,507.
We know about the plant, We know about the patent. Talk to the 6630507 hand. #Patent6630507 #CannabisCommunity #Hand pic.twitter.com/1821p74iaG
— blank (@oatmealislove) August 15, 2016
The patent “proved there was ample evidence to support the medicinal aspects of cannabis — decades of research,” Amy Hilterbran, a medical marijuana advocate who started the trend, told ATTN:. “It proved that cannabis — cannabinoids — were medicinal and effective for numerous ailments, conditions, and that the plant was nontoxic, nonlethal.”
“This one patent disqualified cannabis from even being on the Controlled Substances Act — on several levels,” Hilterban added.
The patent was filed by the U.S. Department of Health and Human Services in 1999. It was published four years later, and information included in the patent description shows that the federal agency has been aware of marijuana’s antioxidant and neuroprotective properties for some time. Researchers found that ingredients in marijuana could be used to treat and prevent age-related, inflammatory, and autoimmune diseases.
“The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia,” an abstract of the patent states.
CNN chief medical corespondent Sanjay Gupta says the issue bothers him, too: “How can the government deny the benefits of medical marijuana even as it holds a patent for those very same benefits?” he asked in a 2014 editorial.
The question is all the more relevant today, after the DEA announced that it would not change marijuana’s classification under federal law. It is to remain Schedule 1 — the strictest category of the Controlled Substances Act, designated for dangerous and addictive drugs with no medical value — in spite of growing evidence that marijuana is relatively safe and medically useful. Though the DEA acknowledges that cannabis is less dangerous than heroin and other Schedule 1 drugs, it justified its decision by arguing that the plant has no accepted medical use.
Latest posts by Baxter Dmitry (see all)
- Ukraine Is Farming Children in Factories for Elite Pedophiles, Russia Is Saving the Children – Media Blackout - March 22, 2023
- Next Plandemic? Big Pharma Developing Bird Flu Vaxx ‘Just In Case’ It Jumps to Humans - March 22, 2023
- Greta Thunberg Given an Honorary Doctorate of Theology By University of Helsinki - March 21, 2023